Clinical trials
catalyst calendar across sponsors →Studies where HOWL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 1 with posted results
Held by 6 tracked-famous managers (Balyasny Asset Management L.P., RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, Squarepoint Ops LLC, MILLENNIUM MANAGEMENT LLC, +1 more) · FINRA short interest 1.3 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 28 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or LymphomaNCT06939283Incidence of Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: WTX-330 | Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | 100 | Aug 2028 | ≤ 743 d | 2026-02-10 |
| Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid TumorsNCT05479812Incidence of Dose Limiting Toxicities (DLTs) in monotherapy and combination therapyNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: WTX-124, pembrolizumab | Metastatic Solid Tumor, Advanced Solid Tumor | 150 | 2026-07-01 | — | 2026-02-09 |
| WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaNCT05678998results2026-01-06Incidence of Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: WTX-330 | Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | 25 | 2024-12-23actual | — | 2026-01-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19